Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial to Investigate the Efficacy and Safety of Oral DA-1229 in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control with Diet and Exercise
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2021
Price :
$35
*
At a glance
- Drugs Evogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2021 Results of a meta-analysis of six randomized controlled trials assessing evogliptin versus placebo and versus other DPP-4 inhibitors conducted following the development of evogliptin, published in the Clinical Therapeutics
- 30 Jan 2015 New trial record